A gene therapy that could provide a permanent cure for sickle cell disease continues to show success through a third wave of patients, researchers report. The therapy, LentiGlobin, restored normal blood function in 35 sickle cell patients who had the one-time procedure, according to clinical trial findings published Dec. 12 in the New England Journal… read on > read on >



















